TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01280643
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01280643
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01280643
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00756782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
Study: NCT00256178
Drug: Lapaquistat acetate and simvastatin
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
Study: NCT04772508
Drug: Taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
Study: NCT04205838
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via infusion
Study: NCT00884221
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
Study: NCT00256178
Drug: Lapaquistat acetate and simvastatin
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
Study: NCT00256178
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
Study: NCT03344679
Drug: Adenosine 12mg
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 12 mg for PECS block
Study: NCT00252655
Drug: Rapamune and Prograf
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00924287
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
Study: NCT02002221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of vildagliptin 50 mg twice daily
Study: NCT01466985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily for 7 days.
Study: NCT00990834
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 80 mg PO daily for one to eight months.
Study: NCT01719835
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m2 IV every 21 days
Study: NCT01719835
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2 IV every 21 days
Study: NCT01719835
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg PO Days 1-5 every 21 days
Study: NCT01093118
Drug: TMI-358
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micro implant monthly x 3
Study: NCT03224182
Drug: Qapzola
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qapzola administered by the intravesical route.
Study: NCT03224182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qapzole-matching placebo administered by the intravesical route.
Study: NCT00506259
Drug: dTR Melatonin (NIH CC PDS)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00506259
Drug: Melatonin CR
Normalized name: Melatonin CR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02269566
Drug: HollisterStier
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
Study: NCT02269566
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of normal saline 3 injections into an inguinal lymph node
Study: NCT01687920
Drug: BAY94-8862 (1.25mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01687920
Drug: BAY94-8862 (2.5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01687920
Drug: BAY94-8862 (5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01687920
Drug: BAY94-8862 (7.5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01687920
Drug: BAY94-8862 (10mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02103777
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
Study: NCT02052687
Drug: LFX453 H1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFX453 high dose cream 1
Study: NCT02052687
Drug: LFX453 H2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFX453 high dose cream 2
Study: NCT02052687
Drug: LFX453 L2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFX453 low dose cream 2
Study: NCT02052687
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream 1
Study: NCT02052687
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream 2
Study: NCT01235520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses, once a day for 52 weeks
Study: NCT01235520
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose level 1, once a day for 52 weeks
Study: NCT01235520
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose level 2, once a day for 52 weeks
Study: NCT03087890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 2 tablets placebo daily for 48 weeks
Study: NCT00357019
Drug: N-acetyl-aspartyl-glutamate (NAAXIA Sine)
Normalized name: acetyl glutamic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02563938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01786395
Drug: UF-021
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01786395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04172701
Drug: Long-acting Muscarinic Antagonists (LAMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT04172701
Drug: Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT02681913
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group receives intermittent warm blood cardioplegia enriched with adenosine
Study: NCT02227394
Drug: Symbicort® Turbohaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
Study: NCT00293436
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01002742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing should be delivered in 250 mg units blinded placebo. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive placebo 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours.
Study: NCT01545583
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT01922115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01925950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01998919
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
Study: NCT02209974
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00746590
Drug: Prolarix (tretazicar co-administered with caricotamide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
Study: NCT02643732
Drug: Placebo (Over-encapsulated tablet)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
Study: NCT04190004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Study: NCT01423916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-34712 placebo
Study: NCT02538185
Drug: Vaccin rabique Pasteur®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02538185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride (NaCl) 0,9%; B. Braun
Study: NCT03881306
Drug: D-TACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-TACE with CalliSpheres-Oxaliplatin
Study: NCT03414294
Drug: K-755 Part A (SAD)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
Study: NCT03414294
Drug: Placebo Part A (SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Study: NCT03414294
Drug: K-755 Part B (MAD)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
Study: NCT03414294
Drug: Placebo Part B (MAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Study: NCT03414294
Drug: K-755 Part C (FE)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
Study: NCT03414294
Drug: K-755 Part D (FE)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
Study: NCT03414294
Drug: K-755 Part E (MAD)
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
Study: NCT03414294
Drug: Placebo Part E (MAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Study: NCT03313336
Drug: EMLA test patch
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
Study: NCT03313336
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
Study: NCT05241145
Drug: IVMED-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
Study: NCT00624754
Drug: lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose 2 puffs b.i.d for 1 month
Study: NCT03921177
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconception to 12-weeks gestation: identical tablet
Study: NCT02522650
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg twice a day for 8 weeks
Study: NCT03246555
Drug: Fimasartan or Fimasartan/Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
Study: NCT03246555
Drug: Perindopril or Perindopril/Indapamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
Study: NCT00626028
Drug: Nitric Oxide for inhalation
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
Study: NCT02282176
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin IV 10mg/kg daily for 10 days
Study: NCT02282176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin placebo (5% Dextrose) daily for 10 days
Study: NCT00626028
Drug: Nitric Oxide plus Oxygen
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
Study: NCT00831779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks
Study: NCT00289354
Drug: Chromium Picolinate (600 mcg Cr) + biotin (2 mg)
Normalized name: biotin / chromium picolinate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00372281
Drug: Cliavist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight \> 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
Study: NCT00554385
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
Study: NCT00696748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 4 mL intramuscular
Study: NCT02506842
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive fluorouracil 2000 mg/m\^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
Study: NCT01982240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets QD for 12 weeks
Study: NCT00813618
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Study: NCT00813618
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Study: NCT02384759
Drug: LV5FU2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00813618
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Study: NCT03224585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days
Study: NCT02169414
Drug: BIA 9-1067 5 mg
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC, Opicapone
Study: NCT02169414
Drug: BIA 9-1067 25 mg
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC, Opicapone
Study: NCT02169414
Drug: levodopa/carbidopa 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediate (standard) release levodopa/carbidopa 100/25
Study: NCT02169414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLC, Placebo
Study: NCT02169414
Drug: levodopa/benserazide 100/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediate (standard) release levodopa/benserazide
Study: NCT00774020
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5mg, i.v. single dose
Study: NCT03762447
Drug: INCB086550
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
Study: NCT01992562
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01753401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
Study: NCT01753401
Drug: Steroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
Study: NCT00250185
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00316238
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02942017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of matching placebo for SAGE-547.
Study: NCT04405245
Drug: AKB-9778 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Razuprotafib opthalmic solution
Study: NCT04405245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for razuprotafib opthalmic solution
Study: NCT01847456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03469323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
Study: NCT01433354
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
Study: NCT00163579
Drug: Bryophyllum
Normalized name: Bryophyllum (Argento Cultum)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00345982
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01171326
Drug: Topical Minocycline Foam FXFM244
Normalized name: minocycline Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
Study: NCT01618162
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected subcutaneously (under the skin) once daily.
Study: NCT02750254
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02625714
Drug: Renexin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
Study: NCT02625714
Drug: SID142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
Study: NCT03370562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of normal saline
Study: NCT01844778
Drug: Tobramycin Inhalation Powder
Normalized name: Tobramycin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
Study: NCT01532869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously weekly, Weeks 0-48
Study: NCT02562807
Drug: Placebo 18mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02562807
Drug: Placebo 9mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04447326
Drug: IC＋CCRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC＋CCRT
Study: NCT04133233
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)